Satellite Meeting – EuroMedLab 2015

REIMS - 26 JUNE

 

HbA_1c and management of diabetes mellitus

in the 21^st Century

 

 

Friday, June 26^th, 2015

Reims, France

 

 

Organized under the auspices of SFBC, SFD*, EFLM*, IFCC*

(*in progress)

*******

 

International Scientific Committee :

 

Dr Michèle Fonfrède, Prof. Philippe Gillery, Prof. Garry John,

Prof. Andrea Mosca, Prof. Bernard Vialettes, Dr Cas Weykamp

 

 

Local Organizing Committee :

 

Dr Aurore Desmons, Prof. Philippe Gillery, Dr Emmanuelle Guillard,

Dr Stéphane Jaisson, Dr Nathalie Schneider

 

 

 

Diabetes mellitus is an increasing global problem for public health which requires the availability of reliable biomarkers for the optimal patient care. Haemoglobin A_1c (HbA_1c) has proved itself to be vital for the management of patients with diabetes and improvements in methods has enabled global targets to be set for treatment and diagnosis.

 

This symposium will present the most recent advances in the management of diabetes mellitus focussing on HbA_1c and new biomarkers. Additionally, new aspects of HbA_1c analysis (e.g. in diabetes diagnosis or point of care testing) will be debated according to both clinical and biological points of views.

 

International experts in the field of diabetes and laboratory medicine, especially those involved in the IFCC reference network on HbA_1c, will give presentations and participate in debates.

 

This meeting is intended for clinical chemists and diabetologists, who will hear the most recent information for use in their daily practice and new perspectives for the future.

 

 

 

 

Chairman /

speaker

09³⁰ – 09⁴⁵  : Welcome addresses

09⁴⁵ – 11⁰⁵ : Session 1 : Diabetes mellitus and HbA_1c :       Michel Marre (FR)     

          global challenges

09⁴⁵ – 10²⁵ : Diabetes Mellitus : Andre Scheen (BE)

The Challenge for the 21^st century

10²⁵ – 11⁰⁵ : HbA_1c: History, Science and Politics Garry John (UK)

11⁰⁵ – 11³⁰ : Tea/Coffee break

11³⁰ – 13¹⁵ : Session 2 : Is HbA_1c fit for its clinical purpose ? Andrea Mosca (IT)

11³⁰ – 12¹⁰ : A standardised HbA_1c is vital for clinical practice Cas Weykamp (NL)

12¹⁰ – 13¹⁵ : Debate : The diagnosis of diabetes mellitus : David Sacks (US)

          a movable feast (pro and con) Eric Kilpatrick (UK)

13¹⁵ – 14³⁰ : Lunch

14³⁰ – 16⁰⁰ : Session 3 : Debate : Using HbA_1c in clinical practice :          Bernard Vialettes (FR)

                    what do I need to know ?

14³⁰ – 15⁰⁰ : Renal Failure! Can I use HbA_1c?         Michel Marre (FR)

15⁰⁰ – 15³⁰ : HbA_1c analysis in the presence of Hb variants              Randie Little (US) 

15³⁰ – 16⁰⁰ : HbA_1c : is POCT good enough?         Sverre Sandberg (NO)

16⁰⁰ – 16³⁰ : Tea/coffee break

16³⁰ – 17³⁰ : Session 4 : Perspective in diabetes biomarkers          Philippe Gillery (FR)

16³⁰ – 16⁵⁰ : HbA_1c beyond diabetes!         Emma English (UK)

16⁵⁰ – 17¹⁰ : Glycated albumin: time for a resurgence         Andrea Mosca (IT)

17¹⁰ – 17³⁰ : Future markers in diabetes monitoring         Michèle Fonfrède (FR)

                   (1,5-anhydroglucitol, AGEs, non invasive technologies)

17³⁰ : Conclusions and end of the meeting